Tags

Type your tag names separated by a space and hit enter

Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost.
Surv Ophthalmol 2001; 45 Suppl 4:S353-60SO

Abstract

PURPOSE

To compare the safety and efficacy of bimatoprost and latanoprost in patients with primary open-angle glaucoma or ocular hypertension.

METHODS

This was a 30-day, multicenter, double-masked, randomized, clinical trial. Patients (n = 64) diagnosed with primary open-angle glaucoma or ocular hypertension were randomly assigned to receive bimatoprost 0.03%, latanoprost 0.005%, or vehicle topically in both eyes once daily, in the evening, for 29 days. The primary endpoint was the reduction in IOP from baseline on day 14 and day 29. Secondary outcome measures included eye examinations and safety parameters.

RESULTS

Bimatoprost and latanoprost significantly lowered IOP from baseline (p <.001). Bimatoprost lowered IOP more than latanoprost at every timepoint measured (bimatoprost: 25-34% reduction, 5.9-8.9 mm Hg; latanoprost: 20-31% reduction, 4.4-7.9 mm Hg), although the between-group differences did not reach statistical significance. Over the 12-hour course of IOP measurements on day 29, bimatoprost provided better diurnal IOP control than latanoprost (p =.0378, area under the curve of diurnal IOP reductions, 1-way ANOVA with pairwise t-test). Both treatment regimens were safe and well tolerated, with no significant between-group differences in reports of specific adverse events. The most common side effect was conjunctival hyperemia, which was similarly apparent in the bimatoprost and latanoprost treatment groups.

CONCLUSIONS

At the end of this 30-day trial, once-daily bimatoprost 0.03% provided better diurnal IOP control than latanoprost and was safe and well tolerated in patients with ocular hypertension and glaucoma.

Authors+Show Affiliations

Clayton Eye Center, Morrow, GA, USA.

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11434938

Citation

DuBiner, H, et al. "Efficacy and Safety of Bimatoprost in Patients With Elevated Intraocular Pressure: a 30-day Comparison With Latanoprost." Survey of Ophthalmology, vol. 45 Suppl 4, 2001, pp. S353-60.
DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol. 2001;45 Suppl 4:S353-60.
DuBiner, H., Cooke, D., Dirks, M., Stewart, W. C., VanDenburgh, A. M., & Felix, C. (2001). Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Survey of Ophthalmology, 45 Suppl 4, pp. S353-60.
DuBiner H, et al. Efficacy and Safety of Bimatoprost in Patients With Elevated Intraocular Pressure: a 30-day Comparison With Latanoprost. Surv Ophthalmol. 2001;45 Suppl 4:S353-60. PubMed PMID: 11434938.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. AU - DuBiner,H, AU - Cooke,D, AU - Dirks,M, AU - Stewart,W C, AU - VanDenburgh,A M, AU - Felix,C, PY - 2001/7/4/pubmed PY - 2001/8/10/medline PY - 2001/7/4/entrez SP - S353 EP - 60 JF - Survey of ophthalmology JO - Surv Ophthalmol VL - 45 Suppl 4 N2 - PURPOSE: To compare the safety and efficacy of bimatoprost and latanoprost in patients with primary open-angle glaucoma or ocular hypertension. METHODS: This was a 30-day, multicenter, double-masked, randomized, clinical trial. Patients (n = 64) diagnosed with primary open-angle glaucoma or ocular hypertension were randomly assigned to receive bimatoprost 0.03%, latanoprost 0.005%, or vehicle topically in both eyes once daily, in the evening, for 29 days. The primary endpoint was the reduction in IOP from baseline on day 14 and day 29. Secondary outcome measures included eye examinations and safety parameters. RESULTS: Bimatoprost and latanoprost significantly lowered IOP from baseline (p <.001). Bimatoprost lowered IOP more than latanoprost at every timepoint measured (bimatoprost: 25-34% reduction, 5.9-8.9 mm Hg; latanoprost: 20-31% reduction, 4.4-7.9 mm Hg), although the between-group differences did not reach statistical significance. Over the 12-hour course of IOP measurements on day 29, bimatoprost provided better diurnal IOP control than latanoprost (p =.0378, area under the curve of diurnal IOP reductions, 1-way ANOVA with pairwise t-test). Both treatment regimens were safe and well tolerated, with no significant between-group differences in reports of specific adverse events. The most common side effect was conjunctival hyperemia, which was similarly apparent in the bimatoprost and latanoprost treatment groups. CONCLUSIONS: At the end of this 30-day trial, once-daily bimatoprost 0.03% provided better diurnal IOP control than latanoprost and was safe and well tolerated in patients with ocular hypertension and glaucoma. SN - 0039-6257 UR - https://www.unboundmedicine.com/medline/citation/11434938/Efficacy_and_safety_of_bimatoprost_in_patients_with_elevated_intraocular_pressure:_a_30_day_comparison_with_latanoprost_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0039625701002120 DB - PRIME DP - Unbound Medicine ER -